Live Panel And Conference Call Scheduled for 7:30 a.m. CDT on September 15, 2014
Data Presented During Poster Session at ASBMR 2014
WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, today announced it will host a panel discussion during the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting at the Hyatt Regency Hotel in Houston, Texas, on Monday, September 15, 2014 at 7:30 a.m. CDT (8:30 a.m. EDT). The panel discussion will also be live streamed via webcast and conference call.
Radius and two prominent leaders in the field of osteoporosis will discuss new data from multiple studies of Radius' investigational drug abaloparatide in women with postmenopausal osteoporosis presented at the ASBMR 2014 Annual Meeting in Houston, Texas. The clinical significance of these data must be confirmed in the ongoing Phase III clinical trial, and all data from the development program are subject to regulatory review. These experts will also discuss key findings in the field more broadly that were presented at ASBMR.
Investors interested in attending the event should RSVP to email@example.com
Date: Monday, September 15th, 2014, 7:30 A.M. CDT (8:30 A.M. EDT)
Location: Hyatt Regency Hotel
Conference Room 1, 6th Floor
1200 Louisiana St, Houston, Texas
Agenda & Participants
- Introductory Comments – Robert Ward, President and Chief Executive Officer
- Osteoporosis Market – Geoffrey Swire, Vice President of Business Development and Strategy
- Target Clinical Profile for Investigational Drug Abaloparatide and Update on Phase III (ACTIVE-SC) trial - Alan Harris, MD/PhD/FRCP, Chief Medical Officer
- New Data On Investigational Drug Abaloparatide Presented at ASBMR – Gary Hattersley, PhD, Chief Scientific Officer
Key Findings at ASBMR 2014 – Outlook for Post-Menopausal Osteoporosis: Roland Baron, D.D.S., Ph.D., Professor of Medicine, Harvard Medical School, Benjamin Leder, M.D., Associate Professor of Medicine, Harvard Medical School, and Radius' Medical Affairs Advisor
Conference Call and Webcast for Investors
Radius will host a conference call and webcast for investors interested in this scientific panel discussion at 7:30 a.m. CDT (8:30 am EDT) on September 15, 2014.
The live call may be accessed by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers, and requesting the Radius Health ASBMR Conference Call. A live webcast of the conference call will be available online from the investor section of Radius' website at www.radiuspharm.com and will be available for replay following the call for 30 days.
About Roland Baron, DDS, PhD
Roland Baron is Professor of Medicine, Harvard Medical School and Massachusetts General Hospital and Chair and Professor of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine. Dr. Baron received his training at the University of Paris Medical School, France, where he was awarded his DDS and then his PhD. He has published more than 300 scientific papers in the field of bone cell and molecular biology. Dr. Baron is the founder and past editor-in-chief of Bone.
Dr. Baron is internationally known for his groundbreaking advances in bone biology and for his contributions to the pre-clinical and clinical development of several osteoporosis drugs. Dr. Baron is a consultant to Radius.
About Benjamin Leder, M.D.
Benjamin Leder is clinical investigator and Endocrinologist at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. He received his MD from Harvard Medical School in 1994 and completed his internal medicine and endocrine training at the Massachusetts General Hospital. Over the past 15 years, his research group has focused on improving the treatment of osteoporosis in men and women, especially in the optimization of anabolic therapies. He has been the principle investigator in many clinical trials and has authored numerous reviews and chapters, all on the topics of bone physiology and osteoporosis treatment
Dr. Leder has been an advisor to Radius since March, 2014.
About the Investigational Drug Abaloparatide
Radius' investigational drug abaloparatide (BA058) is a synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP), a naturally occurring bone-building hormone that we believe has the potential to increase bone mineral density by stimulating new bone formation. hPTHrP is critical in the formation of the skeleton, is involved in the regulation of bone formation, and is able to rebuild bone with lower associated risk of inducing the presence of too much calcium in the blood, known as hypercalcemia, as a side effect. Abaloparatide SC is an investigational drug currently in Phase 3 development for potential use as a daily self-administered injection for the treatment of patients with postmenopausal osteoporosis at high risk of fracture. Topline results from an ongoing Phase 3 pivotal trial comparing abaloparatide SC daily injection to placebo and an active comparator for the prevention of new vertebral fractures are expected at the end of 2014. Radius is also developing the investigational drug abaloparatide TD, for potential use as a short wear-time transdermal patch designed to administer abaloparatide without the need for subcutaneous injection, based on 3M's patented Microstructured Transdermal System technology.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our expectations regarding the scientific panel discussion, the potential benefits of abaloparatide, clinical trials and upcoming events and presentations.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have no product revenues; our need for additional funding, which may not be available; we are not currently profitable and may never become profitable; restrictions imposed on our business by our credit facility, and risks related to default on our obligations under our credit facility; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of abaloparatide SC, and our inability to ensure that abaloparatide SC will obtain regulatory approval or be successfully commercialized; risks related to clinical trials, including having most of our products in early stage clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates; product candidates for which we obtain marketing approval, if any, could be subject to restrictions or withdrawal from the market and we may be subject to penalties; failure to achieve market acceptance of our product candidates; risks related to the use of our limited resources on particular product candidates and not others; delays in enrollment of patients in our clinical trials, which could delay or prevent regulatory approvals; the dependence of our drug development program upon third-parties who are outside our control; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide SC affected the reliability of the data from the study; our reliance on third parties to formulate and manufacture our product candidates; failure to establish additional collaborations; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; developments by competitors may render our products or technologies obsolete or non-competitive; risks related to the fact that our drugs may sell for inadequate prices or patients may be unable to obtain adequate reimbursement; effects of product liability lawsuits on commercialization of our products; failure to comply with obligations of our intellectual property licenses; failure to protect our intellectual property or failure to secure necessary intellectual property related to abaloparatide SC, abaloparatide TD, RAD1901 and/or RAD140; our or our licensors' inability to obtain and maintain patent protection for technology and products; risks related to our compliance with patent application requirements; failure to protect the confidentiality of our trade secrets; risks related to our infringement of third parties' rights; risks associated with intellectual property litigation, including expending substantial resources and distracting personnel from their normal responsibilities; risks related to employees' disclosure of former employers' trade secrets; risks associated with healthcare reform; our failure to comply with healthcare laws and regulations; our exposure to claims associated with the use of hazardous materials and chemicals; inability to successfully manage our growth; risks relating to business combinations and acquisitions; our reliance on key executive officers and advisors; our inability to hire additional qualified personnel; volatility in the price of our common stock; capital appreciation is the only source of gain for our common stock; risks related to increased costs and compliance initiatives associated with operating as a public company; our directors, executive officers and principal stockholders have substantial control over us and could delay or prevent a change in control; future sales of our common stock could depress the price of our common stock; inaccurate or unfavorable information about us could cause the price of our common stock to decline; provisions in our charter documents and Delaware law could discourage takeover attempts; and our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on August 12, 2014, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.comSource:Radius Health